Therapeutic Drug Monitoring of Anti-tumour Necrosis Factor Agents in Inflammatory Bowel Diseases: The Jury Is Still Out

Manasi Agrawal; Marla C Dubinsky; Jean-Frederic Colombel

doi:10.1093/ecco-jcc/jjaa092

Therapeutic Drug Monitoring of Anti-tumour Necrosis Factor Agents in Inflammatory Bowel Diseases: The Jury Is Still Out

J Crohns Colitis. 2020 Sep 7;14(8):1035-1036. doi: 10.1093/ecco-jcc/jjaa092.

Authors

Manasi Agrawal¹, Marla C Dubinsky², Jean-Frederic Colombel¹

Affiliations

¹ The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Division of Pediatric Gastroenterology and Nutrition, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

PMID: 32894298
DOI: 10.1093/ecco-jcc/jjaa092

No abstract available

Keywords: Crohn’s disease; Therapeutic drug monitoring; blood biomarker; clinical remission; disease monitoring; inflammatory bowel diseases; non-invasive biomarker; proactive drug monitoring; reactive drug monitoring; treat-to-target.

Publication types

Editorial

MeSH terms

Biomarkers, Pharmacological / blood
Disease Management
Drug Monitoring* / methods
Drug Monitoring* / standards
Humans
Inflammatory Bowel Diseases* / blood
Inflammatory Bowel Diseases* / diagnosis
Inflammatory Bowel Diseases* / drug therapy
Remission Induction / methods
Tumor Necrosis Factor Inhibitors / pharmacology*

Substances

Biomarkers, Pharmacological
Tumor Necrosis Factor Inhibitors